We believe that this phenomenon is occurring due to the supportive medical infrastructure in Thailand

Tares Krassanairawiwong, Thai FDA  

“We have been working on our clinical trials system, helping to create the strategic clinical research roadmap for Thailand. We are progressing in an effort to make Thailand the centre for regional clinical trials,” proclaims Nares Damrongchai of TCELS. Thailand has recently successfully amended its Drug Act to add regulation for scientific ethics and standards related to clinical trials known as Good Clinical Practice (GCP). “Compliance with GCP standards assures the public that the rights, safety, and well-being of trial subjects are protected, and that the clinical data generated is credible,” confirms the Thai FDA’s Tares Krassanairawiwong.


Many organizations, health institutes, and companies are trying to create the right climate to encourage and develop Thailand’s clinical trial ecosystem. “As one of the leading multinational companies, we are working to be the partner who brings a sustainable solution to the Thai patients, from clinical trials and diagnostics to improving the quality of care and expanding access,” insists Sumalee Kristarnin, country president of Novartis.


Thailand’s strong university hospital system, large patient population, and highly qualified medical personnel make the country a competitive clinical trial destination. “We are going to follow this path in the near future to continue launching clinical research,” proclaims Jadej Thammatacharee, deputy director of the NHSO. Under a unified mission, Krassanairawiwong adds, “We aim to collaborate with all stakeholders to develop an ecosystem that promotes clinical trials in the country and develop our human capital concerning all challenges.”